Global Immunofluorescence Assay Market 2022 to 2031 - Major Players Include Thermo Fisher Scientific,, Abcam, Bio-Rad Laboratories and PerkinElmer - ResearchAndMarkets.com
This report provides strategists, marketers and senior management with the critical information they need to assess the global immunofluorescence assay market.
The "Immunofluorescence Assay Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
This report provides strategists, marketers and senior management with the critical information they need to assess the global immunofluorescence assay market.
The global immunofluorescence assay market is expected to grow from $2.71 billion in 2021 to $2.90 billion in 2022 at a compound annual growth rate (CAGR) of 6.93%. The immunofluorescence assay market is expected to grow to $3.68 billion in 2026 at a compound annual growth rate (CAGR) of 6.14%.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Major players in the immunofluorescence assay market are Thermo Fisher Scientific, Inc., Abcam plc, Bio-Rad Laboratories, Inc., PerkinElmer Inc., Werfen Company, Merck KGaA, Agilent Technologies, Becton Dickinson and Company, Maxvision Biosciences Inc., Zyagen, J. Mitra & Co. Pvt. Ltd., AESKU GROUP GmbH, Vector Laboratories, Inc., EpiGentek Group, and Elabscience, Inc.
The immunofluorescence assay market consists of sales of immunofluorescence assay and related products by entities (organizations, sole traders, partnerships) that refer to equipment and consumables that operate on a technique, which allows the visualization of specific protein and antigen in infected cells based on their ability to react with specific antibodies by binding a particular antibody chemically conjugated with a fluorescent dye. It is a technique used in the laboratory to diagnose diseases of the skin, kidney, heart, cilia, and other organ systems.
The main types of immunofluorescence assay include direct immunofluorescence and indirect immunofluorescence. Direct immunofluorescence refers to a laboratory technique for diagnosing skin, kidney, and other organ system diseases. Direct immunofluorescence utilizes a single antibody that is conjugated directly to fluorescence dye.
The different products of immunofluorescence assay include reagents, instruments, antibodies, kits, consumables & accessories. They are used for the diagnosis of various diseases including cancer, infectious disease, autoimmune disease, and others. They are used by academic and research institutions, pharmaceutical and biotechnology companies, hospitals & diagnostic centres, and contract research organizations.
North America was the largest region in the immunofluorescence assay market in 2021, and it is also expected to be the fastest-growing region in the forecast period. The regions covered in the immunofluorescence assay market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The increasing prevalence of chronic diseases is significantly driving the growth of the immunofluorescence assay market. The changing lifestyle, dietary habits, and improper weight management are contributing to the rapid growth in chronic conditions and a few prolonged chronic infections are leading to cancerous risk.
The growing prevalence of chronic disease is expected to boost demand for immunofluorescence assays as they are widely used in diagnosis and drug development activities.
For instance, according to the study published by the Centers for Disease Control and Prevention, approximately 6 in 10 adults in the USA are affected by chronic disease, and it is also accounting for $3.8 trillion in annual healthcare costs. Therefore, the increasing prevalence of chronic diseases is expected to boost demand for immunofluorescence assay during forecast period.
Technological advancement is a key trend gaining popularity in the immunofluorescence assay market. The companies operating in immunofluorescence assay are focusing on developing technologically innovative products to meet specific technical demands for the diagnostic of new viruses such as COVID-19 and strengthen their market position.
For instance, in March 2022, LumiraDx, a UK-based developer of point-of-care diagnostics, received emergency approval for LumiraDx SARS-CoV-2 Ag Test, a microfluidic immunofluorescence assay, designed for qualitative nucleocapsid protein antigen detection from nasal swab samples.
The countries covered in the immunofluorescence assay market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.
For more information about this report visit https://www.researchandmarkets.com/r/l5e92h
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230120005337/en/